157 related articles for article (PubMed ID: 35337180)
1. Radiosynthesis and Preclinical Evaluation of Bispecific PSMA/FAP Heterodimers for Tumor Imaging.
Hu K; Li L; Huang Y; Ye S; Zhong J; Yan Q; Zhong Y; Fu L; Feng P; Li H
Pharmaceuticals (Basel); 2022 Mar; 15(3):. PubMed ID: 35337180
[TBL] [Abstract][Full Text] [Related]
2. Synthesis and Preclinical Evaluation of Three Novel
Verena A; Zhang Z; Kuo HT; Merkens H; Zeisler J; Wilson R; Bendre S; Wong AAWL; Bénard F; Lin KS
Molecules; 2023 Jan; 28(3):. PubMed ID: 36770755
[TBL] [Abstract][Full Text] [Related]
3. Synthesis and Preclinical Evaluation of Two Novel
Verena A; Merkens H; Chen CC; Chapple DE; Wang L; Bendre S; Wong AAWL; Bénard F; Lin KS
Molecules; 2024 Feb; 29(4):. PubMed ID: 38398552
[TBL] [Abstract][Full Text] [Related]
4. Targeting Fibroblast Activation Protein: Radiosynthesis and Preclinical Evaluation of an
Toms J; Kogler J; Maschauer S; Daniel C; Schmidkonz C; Kuwert T; Prante O
J Nucl Med; 2020 Dec; 61(12):1806-1813. PubMed ID: 32332144
[TBL] [Abstract][Full Text] [Related]
5.
Lindner T; Altmann A; Giesel F; Kratochwil C; Kleist C; Krämer S; Mier W; Cardinale J; Kauczor HU; Jäger D; Debus J; Haberkorn U
EJNMMI Radiopharm Chem; 2021 Aug; 6(1):26. PubMed ID: 34417894
[TBL] [Abstract][Full Text] [Related]
6. Preclinical evaluation and pilot clinical study of [
Hu K; Li J; Wang L; Huang Y; Li L; Ye S; Han Y; Huang S; Wu H; Su J; Tang G
Acta Pharm Sin B; 2022 Feb; 12(2):867-875. PubMed ID: 35256951
[TBL] [Abstract][Full Text] [Related]
7. Radiosynthesis and biological evaluation of 18F-labeled bispecific heterodimer targeted dual gastrin-releasing peptide receptor and prostate-specific membrane antigen for prostate cancer imaging.
Ye S; Li H; Hu K; Li L; Zhong J; Yan Q; Wang Q
Nucl Med Commun; 2022 Mar; 43(3):323-331. PubMed ID: 34919064
[TBL] [Abstract][Full Text] [Related]
8. More advantages in detecting bone and soft tissue metastases from prostate cancer using
Pianou NK; Stavrou PZ; Vlontzou E; Rondogianni P; Exarhos DN; Datseris IE
Hell J Nucl Med; 2019; 22(1):6-9. PubMed ID: 30843003
[TBL] [Abstract][Full Text] [Related]
9. Targeting Prostate-Specific Membrane Antigen (PSMA) with F-18-Labeled Compounds: the Influence of Prosthetic Groups on Tumor Uptake and Clearance Profile.
Bouvet V; Wuest M; Bailey JJ; Bergman C; Janzen N; Valliant JF; Wuest F
Mol Imaging Biol; 2017 Dec; 19(6):923-932. PubMed ID: 28639122
[TBL] [Abstract][Full Text] [Related]
10.
Li H; Ye S; Li Li ; Zhong J; Yan Q; Zhong Y; Feng P; Hu K
Eur J Nucl Med Mol Imaging; 2022 Jul; 49(8):2705-2715. PubMed ID: 35290473
[TBL] [Abstract][Full Text] [Related]
11. Radiosynthesis, preclinical evaluation and pilot clinical PET imaging study of a
Fu L; Huang J; Liu Q; Xie F; Han Y; Sun P; Cao M; Huang Y; Hu K; Tang G
Bioorg Chem; 2023 Dec; 141():106878. PubMed ID: 37774434
[TBL] [Abstract][Full Text] [Related]
12. Rational Design and Pharmacomodulation of
Chen X; Xia D; Zeng X; Meng L; Wang Y; Li H; Zhang J; Zhao Z; Zhuang R; Fang J; Zhang X; Guo Z
J Med Chem; 2024 May; 67(10):8361-8371. PubMed ID: 38726551
[TBL] [Abstract][Full Text] [Related]
13. Automatic radiosynthesis and preclinical evaluation of
Zhou W; Huang S; Jiang Y; Hu K; Wang L; Han Y; Wu H
Amino Acids; 2021 Jun; 53(6):929-938. PubMed ID: 34014365
[TBL] [Abstract][Full Text] [Related]
14. Preclinical Evaluation and Pilot Clinical Study of Al
Liu T; Liu C; Xu X; Liu F; Guo X; Li N; Wang X; Yang J; Yang X; Zhu H; Yang Z
J Nucl Med; 2019 Sep; 60(9):1284-1292. PubMed ID: 30796170
[TBL] [Abstract][Full Text] [Related]
15. IDH-wildtype glioblastomas and grade III/IV IDH-mutant gliomas show elevated tracer uptake in fibroblast activation protein-specific PET/CT.
Röhrich M; Loktev A; Wefers AK; Altmann A; Paech D; Adeberg S; Windisch P; Hielscher T; Flechsig P; Floca R; Leitz D; Schuster JP; Huber PE; Debus J; von Deimling A; Lindner T; Haberkorn U
Eur J Nucl Med Mol Imaging; 2019 Nov; 46(12):2569-2580. PubMed ID: 31388723
[TBL] [Abstract][Full Text] [Related]
16. Synthesis and Preclinical Characterization of the PSMA-Targeted Hybrid Tracer PSMA-I&F for Nuclear and Fluorescence Imaging of Prostate Cancer.
Schottelius M; Wurzer A; Wissmiller K; Beck R; Koch M; Gorpas D; Notni J; Buckle T; van Oosterom MN; Steiger K; Ntziachristos V; Schwaiger M; van Leeuwen FWB; Wester HJ
J Nucl Med; 2019 Jan; 60(1):71-78. PubMed ID: 30237214
[TBL] [Abstract][Full Text] [Related]
17. Synthesis and pre-clinical evaluation of a new class of high-affinity
Kelly J; Amor-Coarasa A; Nikolopoulou A; Kim D; Williams C; Ponnala S; Babich JW
Eur J Nucl Med Mol Imaging; 2017 Apr; 44(4):647-661. PubMed ID: 27847991
[TBL] [Abstract][Full Text] [Related]
18. Synthesis and Preclinical Evaluation of Radio-Iodinated GRPR/PSMA Bispecific Heterodimers for the Theranostics Application in Prostate Cancer.
Abouzayed A; Yim CB; Mitran B; Rinne SS; Tolmachev V; Larhed M; Rosenström U; Orlova A
Pharmaceutics; 2019 Jul; 11(7):. PubMed ID: 31340483
[TBL] [Abstract][Full Text] [Related]
19. Design and Development of
Lindner T; Altmann A; Krämer S; Kleist C; Loktev A; Kratochwil C; Giesel F; Mier W; Marme F; Debus J; Haberkorn U
J Nucl Med; 2020 Oct; 61(10):1507-1513. PubMed ID: 32169911
[TBL] [Abstract][Full Text] [Related]
20. Development of Fibroblast Activation Protein-Targeted Radiotracers with Improved Tumor Retention.
Loktev A; Lindner T; Burger EM; Altmann A; Giesel F; Kratochwil C; Debus J; Marmé F; Jäger D; Mier W; Haberkorn U
J Nucl Med; 2019 Oct; 60(10):1421-1429. PubMed ID: 30850501
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
